ReviewDiabetes, obesity & metabolism2020
Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY.
Review in Diabetes, obesity & metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Efficacy and safety of eplerenone treatment for patients with diabetic nephropathy: A meta-analysis.PloS one · 2022Pooled it
- Population-Wide Screening for Chronic Kidney Disease : A Cost-Effectiveness Analysis.Annals of internal medicine · 2023Trial
- Evaluation of the Clinical Efficacy of the Treatment of Overweight and Obesity in Type 2 Diabetes Mellitus by the Telemedicine Management System Based on the Internet of Things Technology.Computational intelligence and neuroscience · 2022Trial
- Proteomic Mendelian randomization and machine learning reveal causal plasma biomarkers in cardiorenal comorbidity.Renal failure · 2026Article
- Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes.Clinical pharmacology and therapeutics · 2026Article
- Translational advances in diabetic nephropathy management: integrating nanoformulation-based drug delivery systems.Frontiers in medical technology · 2026Review
- Managing Diabetes in Older Adults: Current Approaches in Long-Term Care Facilities.Current diabetes reports · 2025Review
- SA-β-Gal in Kidney Tubules as a Predictor of Renal Outcome in Patients with Chronic Kidney Disease.Journal of clinical medicine · 2024Article
- SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review.Endocrine connections · 2023Review
- Value of SGLT-2 inhibitors in the treatment of chronic kidney disease : Clinical and practical implications.Wiener klinische Wochenschrift · 2023Review
- Emerging Role of Sodium-Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease.International journal of nephrology and renovascular disease · 2023Review
- Emerging roles of Sodium-glucose cotransporter 2 inhibitors in Diabetic kidney disease.Molecular biology reports · 2022Review
- Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes.Cardiovascular diabetology · 2022Review
- Update on the management of diabetes in long-term care facilities.BMJ open diabetes research & care · 2022Review
- Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?Endocrinology and metabolism (Seoul, Korea) · 2022Review
- The Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1.Kidney and dialysis · 2022Article
- Cardiovascular outcomes associated with prescription of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with diabetes and chronic kidney disease.Diabetes, obesity & metabolism · 2022Article
- KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2022Article
- Challenges and opportunities in real-world evidence on the renal effects of sodium-glucose cotransporter-2 inhibitors.Diabetes, obesity & metabolism · 2022Review
- Therapeutic Advances in Diabetic Nephropathy.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
In the past decade, many cardiovascular outcome trials (CVOT) on the efficacy and safety of glucose-lowering agents have been completed. Amongst newer agents available for treatment of type 2 diabetes mellitus (T2DM), sodium-glucose cotransporter-2 (SGLT2) inhibitors have garnered much attention in contemporary clinical practice due to observed benefits on cardiovascular and kidney outcomes among patients with T2DM, as reported in large randomized controlled trials (RCT). These findings are reflected in the updated clinical guidelines of several major professional societies. Herein, we briefly review the mechanism of action of SGLT2 inhibitors and their pleiotropic effects, summarize key findings and limitations of initial CVOTs, then discuss three major kidney disease-focused outcome trials, including the Canagliflozin and Renal Events in Diabetes and Established Nephropathy Clinical Evaluation (CREDENCE) trial as well as two ongoing RCTs: Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure-chronic kidney disease and EMPA-KIDNEY.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.